🔴 Arcturus Therapeutics is trading 5% down today as no clear company-specific catalyst was identified

Arcturus Therapeutics is trading 5.08% down at $16.07, with no clear company-specific negative announcement identified for September 18, 2026.

• Shares reversed part of the September 17 rally, when they closed at $16.93.
• The company announced a September 23 presentation on Phase 2 OTC-deficiency data and an mRNA liver-therapeutics update; coverage does not directly link it to today’s decline.
• Biotech remains broadly strong, suggesting profit-taking or stock-specific trading; confidence is low.